Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

8 18,272 13,272 Total revenue, net 7,401 9,627 48,152 66,692 Costs and expenses: Cost of goods sold 1,713 2,058 8,989 14,109 Research and development 26,274 25,106 104,581 105,939 General and administrative 7,795 6,611 30,260 29,577 Acquired research and development milestone - 6,225 - 13,725 Restructuring charges - - - 10,246 Total costs and expenses 35,782 40,000 143,830 173,596 Loss from operations (28,381) (30,373) (95,678) (106,904) Interest income 972 2,945 5,616 10,699 Interest expense (1,534) (696) (5,635) (2,881) Other income (expense) (3,431) (111) (2,145) 2,215 Loss from continuing operations before income taxes (32,374) (28,235) (97,842) (96,871) Income tax expense/(benefit) - (2,275) - (2,275) Loss from continuing operations (32,374) (25,960) (97,842) (94,596) Discontinued operations: Income (loss) from discontinued operations 32 79 103 4,994 Net loss $(32,342) $(25,881) $(97,739) $(89,602) Basic and diluted loss per share: Continuing operations $(0.83) $(0.67) $(2.51) $(2.67) Discontinued operations - - - 0.15 Net loss per share $(0.83) $(0.67) $(2.51) $(2.52) Shares used in computing basic and diluted net loss per share 39,062 38,753 38,982 35,493 InterMune, Inc. PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS (unaudite
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... an update on the status of the Company,s ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 3,085 and 21 shares of Series A Preferred ...
(Date:5/26/2015)... WORMS, GERMANY – May 26, 2015 ... announces that its manufacturing facility in Worms, Germany ... EXCiPACTâ„¢, an independent organization that certifies manufacturers, suppliers, ... All three Grace facilities that produce its SYLOID® ... have now received GMP certification, following the Curtis ...
(Date:5/26/2015)... 26, 2015   Intrexon Corporation (NYSE: XON ... Gregory Frost , Ph.D., Senior Vice President and Head of ... Healthcare Conference on Wednesday, June 3 rd , at 1:30 ... New York City . About Intrexon Corporation ... the Bioindustrial Revolution with Better DNA ™ to create ...
(Date:5/26/2015)... 26, 2015   PDI , a leader ... that Oakwood Healthcare in Dearborn, Mich. ... entry in Delivering the Difference ... excellence in building collaborative relationships between infection prevention ... facilities.  Oakwood Healthcare,s infection preventionist, ...
Breaking Biology Technology:RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Intrexon to Present at the Jefferies 2015 Global Healthcare Conference 2PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3
... N.J., April 15 Quest Diagnostics,Incorporated (NYSE: ... of the,previously disclosed federal government investigation related to ... manufacturing subsidiary closed,voluntarily in 2006. Quest Diagnostics cooperated ... , Quest Diagnostics will ...
... announced today that it,has completed the formation of ... existing group of Senior Advisers. NexBio recently ... investigational drug,candidate for influenza. The new CAB will ... medicine, helping the company to conduct advanced,product development ...
... BELGIUM, Wis., April 15 Mach One Corporation ... company, announces Monte B. Tobin, the President and ... One,s shareholders:Dear Fellow Shareholders:The mission of Mach One ... global wellness organizations that provide bio-based solutions to ...
Cached Biology Technology:Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006 2NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 2NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 3NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza 4Mach One CEO Letter to Shareholders 2Mach One CEO Letter to Shareholders 3Mach One CEO Letter to Shareholders 4
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2
... are those that occur outside their natural range and ... can be plants, animals or microorganisms that are introduced ... tourism, travel or trade, or when domestic animals become ... the rising cost of invasive species on a global ...
... were once credited with magical healing powers but are now ... but the cause of numerous diseases such as diabetes if ... the vital role played by more complex sugars in many ... This all emerged in a recent workshop organised by ...
... (Jan. 16, 2008) -- Two major federal grants have been ... in New York City. Dr. Kenneth W. Griffin ... from the National Institute on Drug Abuse (NIDA) for research ... previously delivered to urban minority youth attending New York City ...
Cached Biology News:Scientists call for urgent research into 'real' impacts of invasive species 2Scientists call for urgent research into 'real' impacts of invasive species 3ESF's workshop restores good name of sugar 2ESF's workshop restores good name of sugar 32 federal public health grants awarded to Weill Cornell Medical College 2